

FY20 results came in as expected. UNVR recorded FY20 revenue at IDR 42.9 tn (+0.1% YoY), achieving 99.3% of our estimate. Flat sales was mainly driven by declining Foods and Refreshment (F&R) segment by 0.6% YoY, whereas Home and Personal Care (HPC) still saw a 0.4% YoY growth. Several strict mobility restrictions that were imposed by government reduced out-of-home products consumption, though we see that personal hygiene products were favourable amidst the pandemic. Gross margin increased by 100 bps, benefited from lower soft commodity price. Meanwhile, operating margin declined as promotion expense went up due to higher sales contribution from MT. As a result, NPAT came in at IDR 7.2 tn (-3.1% YoY, 99.3% of our estimate).

Assessing quarterly performance. On a quarterly basis, 4Q20 revenue came in at IDR 10.5 tn (-0.5% YoY, -1.6% QoQ). HPC segment sales went down by 6.5% QoQ which might indicate a slow down in consumption recovery. Meanwhile, F&R segment showed a slightly better consumption rate, reflected by a 10.9% QoQ growth on the back of a low base in 3Q20. Finance cost was seen higher, derived from company's additional bank borrowings. This brought 4Q20 net profit to IDR 1.7 tn (-8.4% YoY, -5.1% QoQ).

2021 Outlook. The latest announcement from Statistics Indonesia (BPS) showed that Indonesia's economy contracted by 2.07% YoY, with household consumption declined by 2.63% YoY. This indicates sluggish household spending amidst relatively high social assistance in 2020. Other than that, recent surge on Indonesia's Covid cases in the past month may lead to another strict mobility restriction. Looking into vaccines distribution timeline that was planned to reach its target (67% of total population) in Mar-22 made us believe that the consumption rate might not recover yet in 1H21 but shall gradually pick up in 2H21. We still see that purchasing power will unlikely to return back to pre-pandemic level in 2021, thus we cut our initial FY21 revenue forecast from 4.0% to 2.7% YoY.

We reiterate our NEUTRAL rating on PT Unilever Indonesia (UNVR) with lower 52-week TP of IDR 7,900. Our TP derived from 41.1x FY21F PE (-1SD from its 5-year average). Despite company's modest growth in 2020, we do not see much catalyst to boost company's performance in 2021. We also believe that margin potentially will decline as soft commodity prices has started to recover. Coupled with limited pricing power, we expect moderate growth for both top line and bottom line.

Highlights (IDR Bn)	2019	2020	2021E	2022F	2023F
Revenue	42,923	42,972	44,128	45,713	47,562
% growth	2.7%	0.1%	2.7%	3.6%	4.0%
Gross Profit	22,029	22,457	22,386	23,207	24,166
Net Profit	7,393	7,164	7,342	7,878	8,220
% growth	-18.6%	-3.1%	2.5%	7.3%	4.3%
Gross Margin (%)	51.3%	52.3%	50.7%	50.8%	50.8%
Net Margin (%)	17.2%	16.7%	16.6%	17.2%	17.3%
Return on Equity (%)	116.7%	140.2%	146.9%	150.9%	149.8%
Return on Assets (%)	35.9%	35.0%	36.2%	38.8%	40.2%
EPS (IDR)	194	188	192	207	215

Elvira Natalia

Research Associate

+62 21 392 5550 ext. 610

Elvira.natalia@sinarmassekuritas.co.id**Stock Information**

Sector	Consumer
Bloomberg Ticker	UNVR IJ
Market Cap. (IDR tn)	275.6
Share Out./Float (mn)	38,150/5,725
Current Price	7,225
FY21F Target Price	7,900
Upside	9.3%

Share Price Performance

52W High (05/18/20)	8,800
52W Low (03/20/20)	5,275
52W Beta	0.7
YTD Change	-9.2%

Relative Valuations


Trailing P/E	42.1x
Forward P/E	41.1x
P/BV	59.5x

UNVR 4Q20 Earnings Summary

IDR Bn	4Q19	3Q20	4Q20	%QoQ	%YoY	12M19	12M20	%YoY	%DH	%Cons
Revenue	10,562	10,685	10,516	-1.6%	-0.4%	42,923	42,972	0.1%	99.3%	98.5%
Gross Profit	5,591	5,687	5,586	-1.8%	-0.1%	22,029	22,457	1.9%		
Operating Profit	2,593	2,360	2,365	0.2%	-8.8%	10,118	9,471	-6.4%		
Net Profit	1,883	1,819	1,725	-5.1%	-8.4%	7,393	7,164	-3.1%	99.3%	98.2%
Gross Profit Margin	52.9%	53.2%	53.1%			51.3%	52.3%			
Operating Profit Margin	24.6%	22.1%	22.5%			23.6%	22.0%			
Net Profit Margin	17.8%	17.0%	16.4%			17.2%	16.7%			

Source: Company Data, Sinarmas Investment Research

UNVR 5-Year P/E Band



Source: Bloomberg, Sinarmas Investment Research

Income Statement (IDR Bn)	2019	2020	2021E	2022F	2023F
Revenue	42,923	42,972	44,128	45,713	47,562
% growth	2.7%	0.1%	2.7%	3.6%	4.0%
Cost of Good Sold	(20,894)	(20,515)	(21,742)	(22,506)	(23,396)
Gross Profit	22,029	22,457	22,386	23,207	24,166
% growth	4.4%	1.9%	-0.3%	3.7%	4.1%
Operating Expenses	(11,911)	(12,986)	(12,723)	(13,152)	(13,726)
Opex to Sales (%)	27.7%	30.2%	28.8%	28.8%	28.9%
Other Income (Expenses)	3	(20)	(9)	(9)	(9)
EBIT	10,121	9,451	9,654	10,046	10,431
% growth	-17.9%	-6.6%	2.1%	4.1%	3.8%
EBITDA	10,978	10,360	10,564	11,012	11,444
% growth	-16.7%	-5.6%	2.0%	4.2%	3.9%
Net Financing Income (Expenses)	(219)	(244)	(241)	(198)	(156)
EBT	9,902	9,207	9,413	9,848	10,275
Tax Expenses	(2,509)	(2,043)	(2,071)	(1,970)	(2,055)
Net Income	7,393	7,164	7,342	7,878	8,220
% growth	-18.6%	-3.1%	2.5%	7.3%	4.3%
EPS (IDR)	194	188	192	207	215

Balance Sheet (IDR Bn)	2019	2020	2021E	2022F	2023F
Cash & Equivalents	629	844	886	675	963
Trade Receivables	5,448	5,413	5,415	5,667	5,913
Inventories	2,429	2,463	2,631	2,715	2,814
Other Current Assets	25	108	42	36	33
Total Current Assets	8,531	8,828	8,974	9,093	9,723
Fixed Assets	11,610	11,187	10,848	10,586	10,201
Other Non Current Assets	509	519	524	522	525
Total Assets	20,650	20,534	20,346	20,201	20,449
Short Term Debt	3,046	3,128	2,771	1,784	1,298
Trade Payables	6,595	6,820	6,825	7,086	7,380
Other Current Liabilities	3,425	3,409	3,615	3,757	3,855
Total Current Liabilities	13,066	13,357	13,211	12,627	12,533
Long Term Debt	919	847	929	956	991
Other Non Current Liabilities	1,383	1,393	1,144	1,237	1,328
Total Liabilities	15,368	15,597	15,284	14,820	14,852
Share & APIC	172	172	172	172	172
Retained Earnings	5,110	4,765	4,890	5,209	5,425
Others	-	-	-	-	-
Total Equity	5,282	4,937	5,062	5,381	5,597
Total Liabilities & Equity	20,650	20,534	20,346	20,201	20,449

Source: Company Data, Sinarmas Investment Research

Cash Flow (IDR Bn)	2019	2020	2021E	2022F	2023F
Net Income	7,393	7,164	7,342	7,878	8,220
Dep. & Amortization	857	909	910	966	1,013
Chg. In NWC	(651)	127	108	74	50
CF from Operating	7,599	8,200	8,360	8,918	9,283
Capital Expenditure	(944)	(486)	(571)	(704)	(629)
Chg. in LT Assets	36	(10)	(5)	3	(3)
Chg. in LT Liabs	612	9	(250)	91	93
CF from Investing	(296)	(487)	(826)	(610)	(539)
Chg. in Share & APIC	-	-	-	-	-
Chg. in Debt	2,469	10	(275)	(960)	(452)
Dividends Paid	(9,192)	(7,401)	(7,217)	(7,559)	(8,004)
Others	(303)	(107)	-	-	-
CF from Financing	(7,026)	(7,498)	(7,492)	(8,519)	(8,456)
Chg. in Cash	277	215	42	(211)	288
Beginning Cash	352	629	844	886	675
Ending Cash	629	844	886	675	963

Financial Ratio & Key Assumptions	2019	2020	2021E	2022F	2023F
Profitability					
Return on Equity	116.7%	140.2%	146.9%	150.9%	149.8%
Return on Assets	35.9%	35.0%	36.2%	38.8%	40.2%
Gross Margin	51.3%	52.3%	50.7%	50.8%	50.8%
Operating Margin	23.6%	22.0%	21.9%	22.0%	21.9%
EBITDA Margin	25.6%	24.1%	23.9%	24.1%	24.1%
Net Margin	17.2%	16.7%	16.6%	17.2%	17.3%
Liquidity					
Current Ratio (x)	0.7	0.7	0.7	0.7	0.8
Quick Ratio (x)	0.5	0.5	0.5	0.5	0.5
Solvency					
Debt to Equity (x)	0.8	0.8	0.7	0.5	0.4
Debt to Assets (x)	0.2	0.2	0.2	0.1	0.1
Interest Cov. (x)	44.0	38.0	39.1	49.5	64.7
Valuation					
Price to Earnings (x)	40.8	42.1	41.1	38.3	36.7
Price to Book (x)	57.1	61.0	59.5	56.0	53.8

Source: Company Data, Sinarmas Investment Research

SINARMAS SEKURITAS INVESTMENT RATINGS GUIDE

BUY: Share price may rise by more than 15% over the next 12 months.

ADD: Share price may range between 10% to 15% over the next 12 months.

NEUTRAL: Share price may range between -10% to +10% over the next 12 months.

REDUCE: Share price may range between -10% to -15% over the next 12 months.

SELL: Share price may fall by more than 15% over the next 12 months.

DISCLAIMER

This report has been prepared by PT Sinarmas Sekuritas, an affiliate of Sinarmas Group.

This material is: (i) created based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied upon as such; (ii) for your private information, and we are not soliciting any action based upon it; (iii) not to be construed as an offer to sell or a solicitation of an offer to buy any security.

Opinions expressed are current opinions as of original publication date appearing on this material and the information, including the opinions contained herein, is subjected to change without notice. The analysis contained herein is based on numerous assumptions. Different assumptions could result in materially different results. The analyst (s) responsible for the preparation of this publication may interact with trading desk personnel, sales personnel and other constituencies for the purpose of gathering, integrating and interpreting market information. Research will initiate, update and cease coverage solely at the discretion of Sinarmas Research department. If and as applicable, Sinarmas Sekuritas' investment banking relationships, investment banking and non-investment banking compensation and securities ownership, if any, are specified in disclaimers and related disclosures in this report. In addition, other members of Sinarmas Group may from time to time perform investment banking or other services (including acting as advisor, manager or lender) for, or solicit investment banking or other business from companies under our research coverage. Further, the Sinarmas Group, and/or its officers, directors and employees, including persons, without limitation, involved in the preparation or issuance of this material may, to the extent permitted by law and/or regulation, have long or short positions in, and buy or sell, the securities (including ownership by Sinarmas Group), or derivatives (including options) thereof, of companies under our coverage, or related securities or derivatives. In addition, the Sinarmas Group, including Sinarmas Sekuritas, may act as market maker and principal, willing to buy and sell certain of the securities of companies under our coverage. Further, the Sinarmas Group may buy and sell certain of the securities of companies under our coverage, as agent for its clients.

Investors should consider this report as only a single factor in making their investment decision and, as such, the report should not be viewed as identifying or suggesting all risks, direct or indirect, that may be associated with any investment decision. Recipients should not regard this report as substitute for exercise of their own judgment. Past performance is not necessarily a guide to future performance. The value of any investments may go down as well as up and you may not get back the full amount invested.

Sinarmas Sekuritas specifically prohibits the redistribution of this material in whole or in part without the written permission of Sinarmas Sekuritas and Sinarmas Sekuritas accepts no liability whatsoever for the actions of third parties in this respect. If publication has been distributed by electronic transmission, such as e-mail, then such transmission cannot be guaranteed to be secure or error-free as information could be intercepted, corrupted, lost, destroyed, arrive late or incomplete, or contain viruses. The sender therefore does not accept liability for any errors or omissions in the contents of this publication, which may arise as a result of electronic transmission. If verification is required, please request a hard-copy version.

Additional information is available upon request.

Images may depict objects or elements which are protected by third party copyright, trademarks and other intellectual properties.

©Sinarmas Sekuritas(2021). All rights reserved.